Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q3 2022 · 10-Q
Revenue$42.00K$42.00K−99.3% vs Q3 2021 Net Income-$55.73M-$55.73MN/M vs Q3 2021 EPS Diluted-$0.81-$0.81N/M vs Q3 2021 Operating Income-$57,520,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$48,618,000N/M Margins · derivedOperating margin-136952.4%−136319.0 pt vs Q3 2021
Net margin-132681.0%−132050.3 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 2, 2022 · 33 d after period end